R&D Expenses Disallowance Overturned; ESOP Expenses Sent for Reassessment for Assessment Year 2014-15 &D.

The ITAT partly allowed the appeals for statistical purposes, setting aside lower authorities' disallowance of R&D expenses. It directed that claims be allowed per existing provisions and relevant High Court decisions. The ESOP expenses issue was remitted to the Assessing Officer for reconsideration. The order applied similarly to the Assessment Year 2014-15.

---

---

Issues Involved:
1. Disallowance of deduction of research and development expenditure under section 35(2AB) of the Income Tax Act, 1961.
2. Competency of the Department of Scientific and Industrial Research (DSIR) to approve expenses for claiming weighted deduction under section 35(2AB).
3. Authority of DSIR to approve the quantum of expenditure for deduction under section 35(2AB).
4. Requirement for DSIR approval for in-house Research and Development facility expenses.
5. Allowability of ESOP expenses under section 37(1) of the Income Tax Act.

Detailed Analysis:

1. Disallowance of Deduction of Research and Development Expenditure:
The assessee's claim for weighted deduction under section 35(2AB) was restricted by the Assessing Officer to the amount certified by DSIR, leading to the disallowance of Rs. 52,69,000. The CIT(A) upheld this decision, referencing cases like Electronic Corporation India Ltd. vs ACIT and Coromandel International Ltd vs. ADIT, which emphasized that only expenses approved by DSIR in Form 3CL are eligible for weighted deduction.

2. Competency of DSIR to Approve Expenses:
The CIT(A) held that DSIR is the competent authority to approve expenses for the purpose of claiming weighted deduction under section 35(2AB). This was supported by previous ITAT decisions, which stated that neither the tax officer nor the appellate authority could decide on the expenditure entitled to weighted deduction under this section.

3. Authority of DSIR to Approve the Quantum of Expenditure:
The CIT(A) concluded that DSIR's approval is necessary for the quantum of expenditure claimed under section 35(2AB). The assessee contended that DSIR's role is limited to approving the R&D facility, not the expenses. However, the CIT(A) and the ITAT decisions referenced, such as Coromandel International Ltd vs. ADIT, supported the view that DSIR's certification in Form 3CL is crucial for claiming the deduction.

4. Requirement for DSIR Approval for In-house R&D Facility Expenses:
The CIT(A) and subsequent ITAT decisions consistently held that the approval of DSIR is a prerequisite for claiming weighted deduction on R&D expenses. The assessee's argument that approval is only required for the facility and not for expenses was rejected. The ITAT cited decisions from various High Courts, including CIT vs Claris Lifesciences Ltd. and CIT vs Sandan Vikas India Ltd., which clarified that once the R&D facility is approved, all related expenditures are eligible for deduction, regardless of the date of approval.

5. Allowability of ESOP Expenses:
The assessee raised an additional ground regarding the allowability of ESOP expenses under section 37(1). This ground was admitted for consideration, and the ITAT decided to remit the issue back to the Assessing Officer for reconsideration in light of the ITAT Special Bench decision in Biocon Limited vs DCIT, which was affirmed by the Karnataka High Court.

Conclusion:
The appeals were partly allowed for statistical purposes. The ITAT set aside the orders of the lower authorities regarding the disallowance of R&D expenses, directing that the claims be allowed based on the extant provisions and relevant High Court decisions. The issue of ESOP expenses was remitted to the Assessing Officer for reconsideration. The same order applied mutatis mutandis to the appeal for the Assessment Year 2014-15.

---